Show
Sort by
-
A phase III randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis
-
- Journal Article
- A1
- open access
Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density : a randomized, double-blind, phase 2, parallel group study
-
Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy : a randomised, open-label, phase 3 trial